{"name":"Shanghai Henlius Biotech","slug":"henlius","ticker":"2696.HK","exchange":"HKEX","domain":"henlius.com","description":"Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer. The company also develops HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma, and limited-stage small cell lung cancer; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophagea","hq":"Shanghai, China","founded":2014,"employees":"3762","ceo":"Jason Zhu (Zhu Yi)","sector":"Biosimilars / Biologics","stockPrice":67.35,"stockChange":-1.65,"stockChangePercent":-2.39,"marketCap":"$5.4B","metrics":{"revenue":982539297.8012774,"revenueGrowth":29.2,"grossMargin":74.8,"rdSpend":0,"netIncome":121890911.46623167,"cash":124278939.46459584,"dividendYield":0,"peRatio":38.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":22,"colorKey":"oncology","drugs":[{"name":"EU-sourced Keytruda®","genericName":"EU-sourced Keytruda®","slug":"eu-sourced-keytruda","indication":"Metastatic melanoma","status":"phase_3"},{"name":"EU-Perjeta®","genericName":"EU-Perjeta®","slug":"eu-perjeta","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"EU-sourced YERVOY®","genericName":"EU-sourced YERVOY®","slug":"eu-sourced-yervoy","indication":"Metastatic melanoma","status":"phase_3"},{"name":"HLX04, a bevacizumab biosimilar","genericName":"HLX04, a bevacizumab biosimilar","slug":"hlx04-a-bevacizumab-biosimilar","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"HLX10","genericName":"HLX10","slug":"hlx10","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX10, an engineered anti-PD-1 antibody","genericName":"HLX10, an engineered anti-PD-1 antibody","slug":"hlx10-an-engineered-anti-pd-1-antibody","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX11","genericName":"HLX11","slug":"hlx11","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX22","genericName":"HLX22","slug":"hlx22","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"US-sourced YERVOY®","genericName":"US-sourced YERVOY®","slug":"us-sourced-yervoy","indication":"Metastatic melanoma","status":"phase_3"},{"name":"Cetuximab Injection [Erbitux]","genericName":"Cetuximab Injection [Erbitux]","slug":"cetuximab-injection-erbitux","indication":"Metastatic colorectal cancer","status":"phase_2"},{"name":"Darzalex","genericName":"Darzalex","slug":"darzalex","indication":"Multiple myeloma","status":"marketed"},{"name":"HLX02","genericName":"HLX02","slug":"hlx02","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX03","genericName":"HLX03","slug":"hlx03","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX04","genericName":"HLX04","slug":"hlx04","indication":"Metastatic colorectal cancer (in combination with chemotherapy)","status":"phase_3"},{"name":"HLX04-O","genericName":"HLX04-O","slug":"hlx04-o","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"HLX13","genericName":"HLX13","slug":"hlx13","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX14","genericName":"HLX14","slug":"hlx14","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX15-IV","genericName":"HLX15-IV","slug":"hlx15-iv","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX17","genericName":"HLX17","slug":"hlx17","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX208","genericName":"HLX208","slug":"hlx208","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"carboplatin and nab paclitaxel","genericName":"carboplatin and nab paclitaxel","slug":"carboplatin-and-nab-paclitaxel","indication":"Non-small cell lung cancer (phase 3 development)","status":"phase_3"},{"name":"carboplatin/cisplatin-etoposide","genericName":"carboplatin/cisplatin-etoposide","slug":"carboplatin-cisplatin-etoposide","indication":"Small cell lung cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"HLX301","genericName":"HLX301","slug":"hlx301","indication":"Other","status":"phase_1"},{"name":"HLX48","genericName":"HLX48","slug":"hlx48","indication":"Other","status":"phase_1"},{"name":"HLX26","genericName":"HLX26","slug":"hlx26","indication":"Other","status":"phase_2"},{"name":"HLX43 Dose 1;","genericName":"HLX43 Dose 1;","slug":"hlx43-dose-1","indication":"Other","status":"phase_2"},{"name":"POHERDY","genericName":"PERTUZUMAB-DPZB","slug":"pertuzumab-dpzb","indication":"Other","status":"marketed"},{"name":"US-sourced Keytruda®","genericName":"US-sourced Keytruda®","slug":"us-sourced-keytruda","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"EU-sourced Keytruda®","genericName":"EU-sourced Keytruda®","slug":"eu-sourced-keytruda","phase":"phase_3","mechanism":"Keytruda (pembrolizumab) is a monoclonal antibody that blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.","indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""},{"name":"HLX301","genericName":"HLX301","slug":"hlx301","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EU-Perjeta®","genericName":"EU-Perjeta®","slug":"eu-perjeta","phase":"phase_3","mechanism":"EU-Perjeta is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER family receptors, inhibiting tumor cell growth signaling.","indications":["HER2-positive metastatic breast cancer","HER2-positive early breast cancer (neoadjuvant and adjuvant settings)"],"catalyst":""},{"name":"EU-sourced YERVOY®","genericName":"EU-sourced YERVOY®","slug":"eu-sourced-yervoy","phase":"phase_3","mechanism":"YERVOY (ipilimumab) blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.","indications":["Metastatic melanoma","Advanced renal cell carcinoma","Metastatic colorectal cancer (microsatellite instability-high)","Hepatocellular carcinoma"],"catalyst":""},{"name":"HLX04, a bevacizumab biosimilar","genericName":"HLX04, a bevacizumab biosimilar","slug":"hlx04-a-bevacizumab-biosimilar","phase":"phase_3","mechanism":"HLX04 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Non-small cell lung cancer","Metastatic breast cancer","Ovarian cancer"],"catalyst":""},{"name":"HLX10","genericName":"HLX10","slug":"hlx10","phase":"phase_3","mechanism":"HLX10 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"HLX10, an engineered anti-PD-1 antibody","genericName":"HLX10, an engineered anti-PD-1 antibody","slug":"hlx10-an-engineered-anti-pd-1-antibody","phase":"phase_3","mechanism":"HLX10 is an engineered anti-PD-1 monoclonal antibody that blocks the PD-1 checkpoint on T cells, allowing them to recognize and attack cancer cells.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"HLX11","genericName":"HLX11","slug":"hlx11","phase":"phase_3","mechanism":"HLX11 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"HLX22","genericName":"HLX22","slug":"hlx22","phase":"phase_3","mechanism":"HLX22 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"HLX48","genericName":"HLX48","slug":"hlx48","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"US-sourced YERVOY®","genericName":"US-sourced YERVOY®","slug":"us-sourced-yervoy","phase":"phase_3","mechanism":"YERVOY is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.","indications":["Metastatic melanoma","Adenocarcinoma of the microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors","Colorectal cancer","Renal cell carcinoma","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Cetuximab Injection [Erbitux]","genericName":"Cetuximab Injection [Erbitux]","slug":"cetuximab-injection-erbitux","phase":"phase_2","mechanism":"Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), preventing cancer cell growth and proliferation.","indications":["Metastatic colorectal cancer","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Darzalex","genericName":"Darzalex","slug":"darzalex","phase":"marketed","mechanism":"Lymphocyte differentiation antigen CD38","indications":["Multiple myeloma","Systemic AL amyloidosis"],"catalyst":""},{"name":"HLX02","genericName":"HLX02","slug":"hlx02","phase":"phase_3","mechanism":"HLX02 is a monoclonal antibody that binds to and blocks the PD-1 checkpoint receptor on immune cells, allowing them to recognize and attack cancer cells.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"HLX03","genericName":"HLX03","slug":"hlx03","phase":"phase_3","mechanism":"HLX03 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"HLX04","genericName":"HLX04","slug":"hlx04","phase":"phase_3","mechanism":"HLX04 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.","indications":["Metastatic colorectal cancer (in combination with chemotherapy)","Non-small cell lung cancer","Metastatic breast cancer"],"catalyst":""},{"name":"HLX04-O","genericName":"HLX04-O","slug":"hlx04-o","phase":"phase_3","mechanism":"HLX04-O is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Non-small cell lung cancer","Metastatic breast cancer"],"catalyst":""},{"name":"HLX13","genericName":"HLX13","slug":"hlx13","phase":"phase_3","mechanism":"HLX13 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"HLX14","genericName":"HLX14","slug":"hlx14","phase":"phase_3","mechanism":"HLX14 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"HLX15-IV","genericName":"HLX15-IV","slug":"hlx15-iv","phase":"phase_3","mechanism":"HLX15-IV is a humanized monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"HLX17","genericName":"HLX17","slug":"hlx17","phase":"phase_3","mechanism":"HLX17 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"HLX208","genericName":"HLX208","slug":"hlx208","phase":"phase_2","mechanism":"HLX208 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"HLX26","genericName":"HLX26","slug":"hlx26","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HLX43 Dose 1;","genericName":"HLX43 Dose 1;","slug":"hlx43-dose-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"POHERDY","genericName":"PERTUZUMAB-DPZB","slug":"pertuzumab-dpzb","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"US-sourced Keytruda®","genericName":"US-sourced Keytruda®","slug":"us-sourced-keytruda","phase":"phase_3","mechanism":"Keytruda is a monoclonal antibody that blocks the PD-1 receptor, preventing cancer cells from evading the immune system.","indications":[],"catalyst":""},{"name":"carboplatin and nab paclitaxel","genericName":"carboplatin and nab paclitaxel","slug":"carboplatin-and-nab-paclitaxel","phase":"phase_3","mechanism":"This combination uses carboplatin to cross-link DNA and nab-paclitaxel to stabilize microtubules, together inducing cancer cell death through complementary cytotoxic mechanisms.","indications":["Non-small cell lung cancer (phase 3 development)","Ovarian cancer (potential indication)"],"catalyst":""},{"name":"carboplatin/cisplatin-etoposide","genericName":"carboplatin/cisplatin-etoposide","slug":"carboplatin-cisplatin-etoposide","phase":"phase_3","mechanism":"Carboplatin and cisplatin-etoposide work by interfering with DNA replication in cancer cells, ultimately leading to cell death.","indications":["Small cell lung cancer","Non-small cell lung cancer","Ovarian cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPaGdwYXc1SWhTcFluMkNYb2wwUzhjNzVQVGtlTF81dHR4eUVCTktIMWZQSXQtNFo1cVdwVGFQcWVtQ2pQVkFwU1JlUWlmRU1vcXp0b3JmaHZxMWRBM29fRDkzRXlLQmg5UU5YQURFbmpBbC1mQmtQb2l1YWE3OWFJdUVPRGhFS09LVURKR09yOGJFWFg1Unpyd0JZRzZNcTIxeXhaSDRGZWhWWDdpSHFaWmNEd0JVeXNZTXVhMFp5WQ?oc=5","date":"2025-04-22","type":"pipeline","source":"Yicai Global","summary":"China’s Fosun Pharma to Hike Stake in Henlius After Failed Privatization Bid; Shares Gain - Yicai Global","headline":"China’s Fosun Pharma to Hike Stake in Henlius After Failed Privatization Bid; Shares Gain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBuRUQ2eEZaWmNNMVg3M3hZendHaHR0UGlFTXA1ZEhnSHpkZXdzMXEzYkxjc1A5bWxYdDM3OVVxTkY1QjdQeExXMklIZzFibW1pSl9kUzRBVFd5Q2FPUG9xaw?oc=5","date":"2025-02-05","type":"regulatory","source":"复宏汉霖","summary":"Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)-Media - 复宏汉霖","headline":"Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)-Media - 复宏汉霖","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNQzNvVGlEUTRheEp4RGFvTUdkYzI0ZmRhUUZJRFV5TFlxV1dFSkt3a2d0NWZwRTRCd0ZTcjZTVG1CNUE1NHZCSkJtSFVVUmcwY2QwaTNOcVZPRExBeW9sanhrT2RHZ0hUcldhU1pYRlNXRGplWjlZSGVzN2RvR0dZU0hkLW14Z1VRcVFCLURqUE11LXlvOWZTTXBld29XUnZubDdkLW5BYzVBVWxEejJFYVR0U1BzWmJ3VXVGa1FTMDNTZ0JrQzlmX2NXbGlGYURWZDJWaWFn?oc=5","date":"2025-01-22","type":"pipeline","source":"Reuters","summary":"Henlius Biotech shareholders reject take-private offer from China's Fosun - Reuters","headline":"Henlius Biotech shareholders reject take-private offer from China's Fosun","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNcnNlME00cGc2anYwajBsa2pnTzJxVGNha3pNMkFSVmotZ2xKX29yZFlLU2FkRGx3SkpaZndMQXhaNU1zb001MHBnMS1uQk9xNjJLWjRhMGoyMWJWUGx1U1RvRjRKcjl3QXhMSklkRzlHVWZZMjRjbmlxYnU5emNRb25EQ09kc1Nwanh2TVBBTDN0djA1LVVCNlc1VFFlLVhyMldlM3BZQVVfRUdBUE5B?oc=5","date":"2024-06-25","type":"pipeline","source":"Yicai Global","summary":"Fosun Pharma to Take Private Henlius Biotech for USD692 Million; Shares Jump - Yicai Global","headline":"Fosun Pharma to Take Private Henlius Biotech for USD692 Million; Shares Jump","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFA1Tl9qTkF6LWY2dkJUOGNwUnJkS3dhNHZ4ZWhBaEpNM0xkZUh4T2RKT3BpNEhMYmtaOTgtV0g1eUl3NG8yZS11ekpKNWpIOFRfS2xhYVkzUWZZOHdKWFlwUg?oc=5","date":"2024-01-11","type":"deal","source":"复宏汉霖","summary":"Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene-Media - 复宏汉霖","headline":"Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasof","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE0yeWxPcGR0dHhDcDJJNlhBZmRFMXFsaGhvTmJjUGMtSG5tS0l1dzl2MFNkZW5SZnBLekFvQUhaczhWNmF5Ymk5SGRHWUMzWktOWlh6a3dpUGlNSndYd3dKVw?oc=5","date":"2023-10-27","type":"deal","source":"复宏汉霖","summary":"Henlius Deepens Collaboration with Intas to bring Henlius’ Novel anti-PD-1 mAb Serplulimab to Europe and India - 复宏汉霖","headline":"Henlius Deepens Collaboration with Intas to bring Henlius’ Novel anti-PD-1 mAb Serplulimab to Europe and India - 复宏汉霖","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9xMFdNdzJDYkx3d091dTh1dmk2bjlKQnZ4QVQwb0J4N1UxZ0lDbmJHdk0tS3JzNTNJMXMzaDBBd2FYQXl2UjlCRk5tZGZ5QWdxRDh4UmdnMjBSbDBlSVcybQ?oc=5","date":"2023-09-12","type":"deal","source":"复宏汉霖","summary":"Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA-Media - 复宏汉霖","headline":"Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNeHh5NlNPZ0tIcUUxaTNtVUhpalFEWldNTHYtcmJPRW54NTVlYUQ1YVVvZU5rRzFvQTBGekVzd2M3ejl0dnFKeVR1SDZrY3gzSGNhS1hDVGFkOU9wd2RKbktmc3RTZzY3anNSUlBHQl9qd09uVXBJeFNJRFBGTEdVVFoyMTNKVGNlbF9HcmhIbnEwX3pFVlQwYXpXWWp0dTBXeGpTdGpKcGlzMXNwTWo3OTVMMEoxSlBuOWlOcUE0MjA?oc=5","date":"2023-01-16","type":"deal","source":"BioPharma APAC","summary":"Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab - BioPharma APAC","headline":"Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE0zbEUtQUxTSnZqbm0yZVBERWh6UUNOYkRJN29Rb0xMNWNCRWcycmlMZHRIUmM1X2tkUGZwN1E4M2NsM3pxVjJOXzgtdWg3SC13dDZwNkYtbEZMMEhzMlBzRw?oc=5","date":"2022-06-13","type":"deal","source":"复宏汉霖","summary":"Henlius and Organon Enter into a License and Supply Agreement for Henlius’ Two Biologics in ex-China Countries - 复宏汉霖","headline":"Henlius and Organon Enter into a License and Supply Agreement for Henlius’ Two Biologics in ex-China Countries - 复宏汉霖","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE1scHZLdXhYd1pjNERiT3l0RWhsNkVibG5yZ3BtZU5xX1VqQnhNSXZZQzhYNGpXTkNDdGVZRFR0YmRFZ1lpLUU5NVp4TTZzOUt6c2Exa0F3?oc=5","date":"2020-06-10","type":"pipeline","source":"Yahoo Finance UK","summary":"Shanghai Henlius Biotech, Inc. (2696.HK) stock price, news, quote and history - Yahoo Finance UK","headline":"Shanghai Henlius Biotech, Inc. (2696.HK) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":28,"phaseCounts":{"phase_3":20,"phase_1":2,"phase_2":4,"marketed":2},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":982539287.18979,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":982539287.18979},{"period":"2024-12-31","value":843679425.89473},{"period":"2023-12-31","value":795111237.40893},{"period":"2022-12-31","value":473792597.47209996}],"grossProfit":734654940.59139,"grossProfitHistory":[{"period":"2025-12-31","value":734654940.59139},{"period":"2024-12-31","value":616742892.41174},{"period":"2023-12-31","value":577559238.13069},{"period":"2022-12-31","value":349310859.51293}],"rdSpend":223356777.67146,"rdSpendHistory":[{"period":"2025-12-31","value":223356777.67146},{"period":"2024-12-31","value":152559291.5801},{"period":"2023-12-31","value":164880702.31564},{"period":"2022-12-31","value":205525941.60977998}],"sgaSpend":389324715.30439,"operatingIncome":136705434.5812,"operatingIncomeHistory":[{"period":"2025-12-31","value":136705434.5812},{"period":"2024-12-31","value":138410199.51479},{"period":"2023-12-31","value":106379866.82246},{"period":"2022-12-31","value":-52864661.84484}],"netIncome":121890913.82434,"netIncomeHistory":[{"period":"2025-12-31","value":121890913.82434},{"period":"2024-12-31","value":120922320.8319},{"period":"2023-12-31","value":80473246.67363},{"period":"2022-12-31","value":-102468502.02843}],"eps":1.51,"epsHistory":[{"period":"2025-12-31","value":1.51},{"period":"2024-12-31","value":1.51},{"period":"2023-12-31","value":1},{"period":"2022-12-31","value":-1.28}],"cash":113809529.22993,"cashHistory":[{"period":"2025-12-31","value":113809529.22993},{"period":"2024-12-31","value":113920507.70274},{"period":"2023-12-31","value":145563815.86705},{"period":"2022-12-31","value":100290052.08606}],"totalAssets":1821799765.4746099,"totalLiabilities":1238098834.22448,"totalDebt":530135763.85248,"equity":583700931.2501299,"operatingCashflow":192424586.5474,"operatingCashflowHistory":[{"period":"2025-12-31","value":192424586.5474},{"period":"2024-12-31","value":183031504.19999},{"period":"2023-12-31","value":154444451.80017},{"period":"2022-12-31","value":144672893.0674}],"capex":-176820099.50334,"capexHistory":[{"period":"2025-12-31","value":-176820099.50334},{"period":"2024-12-31","value":-123388902.13462},{"period":"2023-12-31","value":-149068406.97588},{"period":"2022-12-31","value":-201219151.52684}],"freeCashflow":15604487.04406,"dividendsPaid":null,"buybacks":null,"employees":3762,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":67.35,"previousClose":69,"fiftyTwoWeekHigh":92,"fiftyTwoWeekLow":37.15,"fiftyTwoWeekRange":"37.15 - 92.0","fiftyDayAverage":73.85,"twoHundredDayAverage":70.48,"beta":0.52,"enterpriseValue":5800674813.121536,"forwardPE":37.2,"priceToBook":8.02,"priceToSales":5.49,"enterpriseToRevenue":5.9,"enterpriseToEbitda":33.84,"pegRatio":0,"ebitda":171430060.48522496,"ebitdaMargin":17.4,"freeCashflow":-135948576.1348128,"operatingCashflow":192424581.83118334,"totalDebt":530135763.85248,"debtToEquity":90.8,"currentRatio":0.71,"returnOnAssets":4.4,"returnOnEquity":23.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":7,"targetMeanPrice":102.52,"targetHighPrice":120.15,"targetLowPrice":90.7,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":74,"institutionHeldPercent":21.5,"sharesOutstanding":346074397,"floatShares":137569417,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":1.74,"epsForward":1.81,"revenuePerShare":12.27,"bookValue":8.4,"officers":[{"age":46,"name":"Dr. Jun  Zhu","title":"CEO & Executive Director"},{"age":57,"name":"Ms. Wei  Huang","title":"President"},{"age":61,"name":"Dr. Shi-Kau  Liu","title":"Co-founder & Head of Strategy Advisory Committee"},{"age":62,"name":"Dr. Wei-Dong  Jiang","title":"Co-Founder & Co-Head of Innovative Advisory Committee"},{"age":46,"name":"Mr. Yingbo  Mao","title":"VP & CFO"},{"age":47,"name":"Dr. Jijun  Yuan","title":"Chief Scientific Officer"},{"age":null,"name":"Ms. Miaojie  Chen","title":"Vice President of Legal & Compliance"},{"age":37,"name":"Ms. Yan  Wang","title":"GM of Public Relations, Joint Company Secretary & Board Secretary"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.henlius.com","phone":"86 21 3339 5800"}}